These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29327474)

  • 1. Long-term effects of intralymphatic immunotherapy (ILIT) on canine atopic dermatitis.
    Timm K; Mueller RS; Nett-Mettler CS
    Vet Dermatol; 2018 Apr; 29(2):123-e49. PubMed ID: 29327474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of short-term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double-blinded, controlled, randomised study.
    van Amersfort K; Vernooij JCM; van der Lee A
    Vet Dermatol; 2023 Oct; 34(5):373-384. PubMed ID: 37186491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of subcutaneous, intralymphatic and sublingual immunotherapy for the long-term control of dogs with nonseasonal atopic dermatitis.
    Fischer NM; Rostaher A; Favrot C
    Vet Dermatol; 2020 Oct; 31(5):365-e96. PubMed ID: 32537789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intralymphatic immunotherapy: An effective and safe alternative route for canine atopic dermatitis].
    Fischer N; Rostaher A; Favrot C
    Schweiz Arch Tierheilkd; 2016 Sep; 158(9):646-652. PubMed ID: 27655164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis - a pilot study.
    Mueller RS; Veir J; Fieseler KV; Dow SW
    Vet Dermatol; 2005 Feb; 16(1):61-8. PubMed ID: 15725107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, double-blinded comparison between subcutaneous rush and intralympathic allergen immunotherapy induction in atopic dogs.
    Mueller RS; Zablotski Y; Baumann K; Boehm T; Kasper B; Klinger C; Monke M; Udraite-Vovk L; Weitzer T; Gedon NKY
    Vet Dermatol; 2023 Apr; 34(2):91-98. PubMed ID: 36424528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rush immunotherapy with alum-precipitated allergens in canine atopic dermatitis.
    Hobi S; Mueller RS
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2014; 42(3):167-73. PubMed ID: 24920143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the safety of an abbreviated course of injections of allergen extracts (rush immunotherapy) for the treatment of dogs with atopic dermatitis.
    Mueller RS; Bettenay SV
    Am J Vet Res; 2001 Mar; 62(3):307-10. PubMed ID: 11277192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of regionally-specific immunotherapy for the management of canine atopic dermatitis.
    Plant JD; Neradilek MB
    BMC Vet Res; 2017 Jan; 13(1):4. PubMed ID: 28056956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double blind, randomized, placebo controlled trial of the efficacy, quality of life and safety of food allergen-specific sublingual immunotherapy in client owned dogs with adverse food reactions: a small pilot study.
    Maina E; Cox E
    Vet Dermatol; 2016 Oct; 27(5):361-e91. PubMed ID: 27426929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of allergen-specific immunotherapy in atopic dogs with Malassezia hypersensitivity: a retrospective study of 16 cases.
    Åberg L; Varjonen K; Åhman S
    Vet Dermatol; 2017 Dec; 28(6):633-e157. PubMed ID: 28748560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of low dose immunotherapy in the treatment of canine atopic dermatitis: a prospective, double-blinded, clinical study.
    Colombo S; Hill PB; Shaw DJ; Thoday KL
    Vet Dermatol; 2005 Jun; 16(3):162-70. PubMed ID: 15960629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hyposensitization on atopic dermatitis in dogs.
    Willemse A; Van den Brom WE; Rijnberk A
    J Am Vet Med Assoc; 1984 May; 184(10):1277-80. PubMed ID: 6376442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on Allergen Immunotherapy.
    Mueller RS
    Vet Clin North Am Small Anim Pract; 2019 Jan; 49(1):1-7. PubMed ID: 30227970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitation of canine regulatory T cell populations, serum interleukin-10 and allergen-specific IgE concentrations in healthy control dogs and canine atopic dermatitis patients receiving allergen-specific immunotherapy.
    Keppel KE; Campbell KL; Zuckermann FA; Greeley EA; Schaeffer DJ; Husmann RJ
    Vet Immunol Immunopathol; 2008 Jun; 123(3-4):337-44. PubMed ID: 18423890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the efficacy rate and time-to-efficacy of subcutaneous immunotherapy in dogs with atopic dermatitis.
    Tham HL; Olivry T
    Vet Dermatol; 2022 Apr; 33(2):155-e44. PubMed ID: 34883529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy.
    Griffin CE; Hillier A
    Vet Immunol Immunopathol; 2001 Sep; 81(3-4):363-83. PubMed ID: 11553398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the long-term efficacy and safety of subcutaneous immunotherapy for atopic dermatitis.
    Zhou J; Chen S; Song Z
    Allergy Asthma Proc; 2021 Mar; 42(2):e47-e54. PubMed ID: 33685566
    [No Abstract]   [Full Text] [Related]  

  • 19. The safety of rush immunotherapy in the management of canine atopic dermatitis-230 cases.
    Weitzer T; Mueller R
    Vet Dermatol; 2023 Oct; 34(5):385-392. PubMed ID: 37157908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic adipose-derived mesenchymal stem cell therapy in dogs with refractory atopic dermatitis: clinical efficacy and safety.
    Villatoro AJ; Hermida-Prieto M; Fernández V; Fariñas F; Alcoholado C; Rodríguez-García MI; Mariñas-Pardo L; Becerra J
    Vet Rec; 2018 Dec; 183(21):654. PubMed ID: 30158120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.